Cue Biopharma (CUE) Projected to Post Earnings on Monday

Cue Biopharma (NASDAQ:CUE) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Cue Biopharma to post earnings of ($0.10) per share and revenue of $1.00 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 7:00 AM ET.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Monday, March 16th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $21.94 million for the quarter. Cue Biopharma had a negative return on equity of 165.19% and a negative net margin of 96.85%. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Trading Up 0.6%

Cue Biopharma stock opened at $0.27 on Monday. Cue Biopharma has a 52 week low of $0.23 and a 52 week high of $1.05. The stock has a market cap of $25.86 million, a P/E ratio of -0.83 and a beta of 1.52. The stock has a 50 day moving average of $0.31 and a 200-day moving average of $0.51.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cue Biopharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cue Biopharma currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Boothbay Fund Management LLC acquired a new position in shares of Cue Biopharma in the 3rd quarter worth approximately $439,000. Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma in the 3rd quarter valued at approximately $62,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares in the last quarter. Finally, Stifel Financial Corp raised its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.